Clinical outcomes of Enterobacteriaceae infections stratified by carbapenem MICs. - Wikidata - wikimedia - TriplyDB

Clinical outcomes of Enterobacteriaceae infections stratified by carbapenem MICs.

Clinical outcomes of Enterobacteriaceae infections stratified by carbapenem MICs.

http://www.wikidata.org/entity/Q34916515

about

Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options Carbapenem-Resistant Enterobacteriaceae Infections in Children.High minimum inhibitory concentration of imipenem as a predictor of fatal outcome in patients with carbapenem non-susceptible Klebsiella pneumoniae KlebSeq, a Diagnostic Tool for Surveillance, Detection, and Monitoring of Klebsiella pneumoniae Population Pharmacokinetic Analysis of Doripenem after Intravenous Infusion in Korean Patients with Acute Infections.Carbapenem susceptibility breakpoints, clinical implications with the moving target.Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.In Vitro Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program).Risk factors and clinical outcomes for carbapenem-resistant Enterobacteriaceae nosocomial infections.Is This the Carbapenemase Test We've Been Waiting for? A Multicenter Evaluation of the Modified Carbapenem Inactivation Method.

P2860

Q21146707-95521BAB-E6E3-4ABF-9BAE-8B77A46324A6 Q37154718-8138844C-B2AF-4CFC-BD58-798F842A266F Q37227817-B7C3B8E6-B8FD-4F29-BE4C-8EE86CF110D7 Q37280606-6744DD4C-F233-48A2-B831-CCEEB5BE420D Q38405565-4824195E-65BF-41E3-960B-94D87467B25F Q38751264-5D77BDD5-A156-495D-91FC-9DD44C332A99 Q40187323-540862AC-9E37-494B-8E7E-F0FA11799775 Q40287334-84388D45-73B3-4C13-9FEB-DC9D814379EC Q40617815-08D9E2C3-9608-4038-9A28-8059D7322C66 Q46487479-B0ECB83C-18B7-490C-A0BD-5B163B34722A

P2860

Clinical outcomes of Enterobacteriaceae infections stratified by carbapenem MICs.

http://www.wikidata.org/entity/Q34916515

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Clinical outcomes of Enterobacteriaceae infections stratified by carbapenem MICs.

@ast

Clinical outcomes of Enterobacteriaceae infections stratified by carbapenem MICs.

@en

Clinical outcomes of Enterobacteriaceae infections stratified by carbapenem MICs.

@nl

type

label

Clinical outcomes of Enterobacteriaceae infections stratified by carbapenem MICs.

@ast

Clinical outcomes of Enterobacteriaceae infections stratified by carbapenem MICs.

@en

Clinical outcomes of Enterobacteriaceae infections stratified by carbapenem MICs.

@nl

prefLabel

Clinical outcomes of Enterobacteriaceae infections stratified by carbapenem MICs.

@ast

Clinical outcomes of Enterobacteriaceae infections stratified by carbapenem MICs.

@en

Clinical outcomes of Enterobacteriaceae infections stratified by carbapenem MICs.

@nl

P1433

Q34916515-D0A911AD-3F03-42D4-AA18-198E954E4B3D

P1476

Q34916515-C623A777-3666-4366-824B-2EA49A8543A0

P2093

Q34916515-5CE70BFF-DA1F-4405-8381-758B2A13EC5F

Q34916515-CE623C41-5974-43CF-8967-EF7A30CACF14

P2860

Q34916515-12ADBE1E-396B-4BEA-B26A-47813ED30C41

Q34916515-1696C3AA-0188-41C1-B4FE-226A885214A0

Q34916515-175406C6-366B-4D6E-B8CB-8DCDD86070FC

Q34916515-193CCD04-892E-4E44-A217-A97A091EB330

Q34916515-3F79305E-3DE1-40E9-B553-ECE79711C560

Q34916515-55B4FC58-266A-4393-A81A-821C00D8FFBD

Q34916515-6F3C59EC-113D-48E9-8586-BB285D1FA90D

Q34916515-7907B873-17ED-49D4-8239-022802BD5479

Q34916515-B2545A6A-A931-4129-B612-7729388416C9

Q34916515-B4F0A7D3-B783-4DBC-BEE9-FB015C4F29D7

P304

Q34916515-68185357-D17B-49F8-A121-5B49CDDADF42

P31

Q34916515-0DEE2FF5-74CA-49D2-83C8-E6524E5F4A79

P356

Q34916515-2B3E7A7B-F120-4D84-8D2F-D985BCA3D3FC

P407

Q34916515-D323BCBA-9145-4520-AE40-FF0CFAB64CE4

P433

Q34916515-283EE8E4-3E90-44F7-ABB5-F5C57516E134

P478

Q34916515-26822BEC-B7D9-4514-830D-CC694A9A7A5F

P577

Q34916515-F4FEFE69-17C7-4F88-8881-3A258C3414F3

P698

Q34916515-02B38514-9C58-4874-A511-D13AEC6558D7

P921

Q34916515-F3C220AF-2A54-446C-A2CD-D3C2D0E14FD0

P932

Q34916515-0676DA0A-4562-4EA8-BDB1-5B8893E2D224

P356

P1433

Journal of Clinical Microbiology

P1476

Clinical outcomes of Enterobacteriaceae infections stratified by carbapenem MICs.

@en

P2093

Jerod L Nagel

http://www.w3.org/2001/XMLSchema#string

Twisha S Patel

http://www.w3.org/2001/XMLSchema#string

P2860

Evaluation of clinical outcomes in patients with bloodstream infections due to Gram-negative bacteria according to carbapenem MIC stratification

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.

Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies.

Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms.

Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America.

Effect of differences in MIC values on clinical outcomes in patients with bloodstream infections caused by gram-negative organisms treated with levofloxacin.

Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?

Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008).

Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.

P304

201-205

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JCM.03057-14

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25378572

http://www.w3.org/2001/XMLSchema#string

P921

carbapenem antibiotic

P932

4290923

http://www.w3.org/2001/XMLSchema#string